Cargo Therapeutics, INC

CARGO Therapeutics, Inc. has completed its acquisition by Concentra Biosciences, LLC, with shareholders receiving $4.379 cash and a contingent value right per share.

CARGO Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $4.379 per share in cash plus a contingent value right.

CARGO Therapeutics, Inc. has assigned its San Carlos, California lease, incurring a $36.3 million cash payment, as it continues to suspend development efforts and explore strategic alternatives.

CARGO Therapeutics, Inc. announced the successful election of three Class II directors and the ratification of Deloitte & Touche LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

CARGO Therapeutics suspends pipeline development, reduces workforce by 90%, appoints interim CEO, and explores strategic options including a potential reverse merger.

CARGO Therapeutics presents a corporate update highlighting its allogeneic vector platform designed to overcome limitations in cell therapy and the progress of its CRG-023 program targeting B-cell malignancies.

CARGO Therapeutics, Inc. announced a definitive merger agreement with Concentra Biosciences, LLC, following significant restructuring, workforce reductions, and the discontinuation of its lead cell therapy program.

CARGO Therapeutics discontinues its Phase 2 firi-cel study and suspends pipeline development, initiating a strategic review process that could lead to a reverse merger, business combination, or cash sale.

CARGO Therapeutics' Q3 2024 report highlights increased R&D spending and a net loss, but also notes sufficient cash reserves to support operations through 2026.

CARGO Therapeutics, a clinical-stage biotechnology company, reported a net loss of $44.3 million for the second quarter of 2024, alongside updates on its clinical programs and financial position.

CARGO Therapeutics reports a net loss of $35.8 million for the first quarter of 2024, alongside updates on clinical trials and financial position.

CARGO Therapeutics reports its 2024 financial results, highlighting progress in its clinical programs and strategic adjustments.

CARGO Therapeutics' 10-K filing details its clinical-stage progress in developing next-generation cell therapies for cancer, particularly focusing on its lead program CRG-022.

A director of CARGO Therapeutics, Kapil Dhingra, disposed of 25,000 stock options following the company's merger with Concentra Biosciences.

CARGO Therapeutics Director Krishnan Viswanadhan disposed of all beneficial ownership in the company following its acquisition by Concentra Biosciences.

CARGO Therapeutics Director David Lubner's stock options were canceled and converted into cash and contingent value rights following the company's acquisition by Concentra Biosciences.

A director of CARGO Therapeutics, Inc. disposed of stock options following the company's acquisition by Concentra Biosciences, LLC.

CARGO Therapeutics Director Jane Henderson disposed of 25,000 stock options following the company's acquisition by Concentra Biosciences for $4.379 cash and one CVR per share.

A director of CARGO Therapeutics, Abraham Bassan, disposed of stock options following the company's acquisition by Concentra Biosciences.

Cargo Therapeutics has scheduled its 2025 Annual Meeting for June 18, 2025, and is urging stockholders to vote on the election of directors and the ratification of the company's independent auditor.

CARGO Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections and auditor ratification.

Cargo Therapeutics will hold its annual stockholder meeting on June 4, 2024, to vote on the election of directors and ratification of the company's independent auditor.

CARGO Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, to vote on the election of directors and ratification of the independent auditor.

CARGO Therapeutics is registering the resale of up to 6,471,000 shares of its common stock by selling stockholders following a private placement that generated $110 million in gross proceeds.

Tang Capital reports the completion of a merger with Cargo Therapeutics through Concentra Merger Sub VII, resulting in Cargo Therapeutics becoming a wholly-owned subsidiary of Concentra Biosciences.

Cargo Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $4.379 per share in cash plus one contingent value right.

Tang Capital Management and affiliated entities have disclosed a 5.9% beneficial ownership stake in CARGO Therapeutics, Inc., acquired for investment purposes with potential for strategic discussions.

Samsara BioCapital, L.P., along with its general partner and managing member, Srinivas Akkaraju, reported a complete divestment of their beneficial ownership in Cargo Therapeutics, Inc. common stock.

Nextech VII GP S.a. r.l. and affiliated entities report zero beneficial ownership in Cargo Therapeutics, Inc. common stock, indicating a full divestment from their previously reported stake.

Madison Avenue Partners and affiliated entities have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of CARGO Therapeutics, Inc.

RTW Investments, LP and Roderick Wong, M.D. have reported a 0.0% beneficial ownership in Cargo Therapeutics, Inc. common stock.

A group of investment entities led by Eli Samaha has reported a 9.1% passive ownership stake in CARGO Therapeutics, Inc., holding over 4.19 million shares.

RTW Investments and Roderick Wong have disclosed a 6.4% beneficial ownership stake in Cargo Therapeutics, Inc., holding over 3 million shares.